Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 18/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 10/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.36 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19075622 | 0.88 | SCN9A (0.43) | SCN9ASCN5ACYP2C9CYP3A4AAK1 | |
| SCHEMBL20697770 | 0.82 | SCN9A (0.40) | SCN9ASCN5ACYP2C9CYP3A4AAK1 | |
| SCHEMBL15599286 | 0.76 | SCN9A (0.45) | SCN9ASCN5ACYP2C9CYP3A4AAK1 | |
| SCHEMBL17430826 | 0.75 | SCN9A (0.42) | SCN9ASCN5ACYP2C9CYP3A4AAK1 | |
| SCHEMBL16858566 | 0.74 | SCN9A (0.44) | SCN9ASCN5ACYP2C9CYP3A4 | |
| SCHEMBL17244885 | 0.74 | SCN9A (0.44) | SCN9ASCN5ACYP2C9CYP3A4 | |
| SCHEMBL10324676 | 0.74 | SCN9A (0.44) | SCN9ASCN5ACYP2C9CYP3A4 | |
| SCHEMBL365208 | 0.74 | SCN9A (0.47) | SCN9ASCN5ACYP2C9CYP3A4 | |
| SCHEMBL15599250 | 0.73 | SCN9A (0.43) | SCN9ASCN5ACYP2C9CYP3A4 | |
| SCHEMBL16082402 | 0.72 | SCN9A (0.44) | SCN9ASCN5ACYP2C9CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885SCN5A 1598/4885CYP2C9 692/4885 |
| US-10005724-B2 | Therapeutic compounds and methods of use thereof | RDX, C1R, MTX1 | SCN9A 2337/4885SCN5A 1598/4885CYP2C9 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.